Validation of obesity-related diagnosis codes in claims data.
Suissa K, Schneeweiss S, Lin KJ, Brill G, Kim SC, Patorno E.
Diabetes Obes Metab. 2021 Aug 02. PMID: 34338404
Other Academic
Seoyoung C. Kim
Other Positions
Associate Professor of Medicine
Medicine
Brigham and Women's Hospital
Links
Overview
Seoyoung C. Kim, M.D, Sc.D, M.S.C.E, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. She is the Director of the Program in Rheumatologic, Immunologic, and Musculoskeletal PharmacoEpidemiology (PRIME).
She is board-certified in Rheumatology, and co-appointed in the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital. Her research focuses on comparative safety and effectiveness of medications for the rheumatic diseases as well as health services/outcome research in Rheumatology.
Dr. Kim is an Associate Editor for Arthritis Care & Research and ACR Open Rheumatology and has served on a number of Committees for the American College of Rheumatology and the International Society for Pharmacoepidemiology.
BWH DOM Early Career Mentoring Award
Brigham and Women's Hospital
Harvard Catalyst Clinical Research Center Batch Sample Analysis and Assay Validation Award
Harvard Catalyst
Chair's Research Award
Brigham and Women's Hospital, DOM
Bibliography
Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis.
Jin Y, Chen SK, Lee H, Landon JE, Merola JF, Kim SC.
J Manag Care Spec Pharm. 2021 Aug. 27(8):1106-1117. PMID: 34337987
Utilization of targeted disease-modifying anti-rheumatic drugs (DMARDs) for managing rheumatoid arthritis in the last decade: A two-country comparison.
Park SH, Jeon HL, Kim SC, Hillen J, Gadzhanova S, Shin JY, Pratt N.
Int J Clin Pharmacol Ther. 2021 Jul 08. PMID: 34236304
Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Pawar A, Desai RJ, He M, Bessette L, Kim SC.
ACR Open Rheumatol. 2021 Jul 01. PMID: 34196497
Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases.
Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, Mostaghimi A, Silverberg JI, Schneeweiss S.
JAMA Dermatol. 2021 Jul 01. 157(7):805-816. PMID: 34037662
Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden.
Shin A, Lee YJ, Lee EB, Song YW, Kim SC, Kang EH.
Rheumatology (Oxford). 2021 Jun 18. 60(6):2755-2764. PMID: 33188421
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
Cromer SJ, D'Silva KM, Yu EW, Landon J, Desai RJ, Kim SC.
J Gen Intern Med. 2021 Jun 07. PMID: 34100235
Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease.
Kirchgesner J, Desai RJ, Beaugerie L, Kim SC, Schneeweiss S.
Clin Pharmacol Ther. 2021 May 24. PMID: 34027993
Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis.
Jin Y, Lee H, Lee MP, Landon JE, Merola JF, Desai RJ, Kim SC.
Arthritis Care Res (Hoboken). 2021 May 10. PMID: 33973371
Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning.
Johansson FD, Collins JE, Yau V, Guan H, Kim SC, Losina E, Sontag D, Stratton J, Trinh H, Greenberg J, Solomon DH.
J Rheumatol. 2021 May 01. PMID: 33934070